CN105535095A - Medicine composition for treating liver ascites - Google Patents
Medicine composition for treating liver ascites Download PDFInfo
- Publication number
- CN105535095A CN105535095A CN201610047141.8A CN201610047141A CN105535095A CN 105535095 A CN105535095 A CN 105535095A CN 201610047141 A CN201610047141 A CN 201610047141A CN 105535095 A CN105535095 A CN 105535095A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ethanol
- percent concentration
- weight percent
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a medicine composition for treating liver ascites and a preparation method thereof. The medicine composition is prepared from macluraxanthone, dicranopteris linearis and chekiangensis c. y. wu in a matching mode. Various dosage forms can be prepared according to a normal formulation technology, and the medicine composition has the remarkable effect on treating the liver ascites.
Description
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of hepatic ascites and preparation method thereof.
Background technology
Cirrhotic ascites (abbreviation hepatic ascites) is the result of various Chronic Liver disease of ZANG-organs development, is still obstinate disease so far.Though western medical treatment cirrhotic ascites has certain curative effect, late result is not good enough, and relapse rate is high, and complication is many, and huge medical expense also makes patient hang back.The traditional Chinese medical science uses Chinese medicine from too many levels, Mutiple Targets on dialectical basis, and treatment cirrhotic ascites, curative effect is certainly, safe, economical, has the unrivaled superiority of doctor trained in Western medicine.But current Chinese medicine is observed mainly using the change of clinical symptoms and sign as the evaluation to therapeutic effect, less to objectivity index study.Therefore on differentiation of tcm basis in conjunction with modern Western medicine theory, carry out the research for the treatment of cirrhotic ascites herbal pharmacology, facing the physical and chemical index of card in conjunction with microcosmic as the standard evaluating clinical efficacy, is the direction of Hepatocirrhosis in Chinese Herbal Medicine ascites research.
Maclura aurantiaca ketone (Macluraxanthone): CAS 5848-14-6, molecular formula C
23h
22o
6, molecular weight 394.42.[pharmacological action] expelling worm.[ingredient origin] Garcinia maingayii bakupari, Moraceae Maclura aurantiaca peel of stem.
Wolf beanstalk grass: this product is Diplopterygium glaucum (Thunb ex Houtt) Nakai section Dicranopteris dichotoma platymiscium ferrum Dicranopteris dichotoma Dicranopterislinearis(Burm.f.) Underw. ［ PolypodiumlineareBurm.f.; GleichenialinearisClarke ］ herb.The whole year all can gather, and cleans, removes fibrous root and petiole, rhizome and leaf are separated, dry.[nature and flavor] are bitter; Sweet; Flat.[function cures mainly] stops blooding; Synthetism; Clearing away heat-damp and promoting diuresis; Removing toxic substances and promoting subsidence of swelling.Main metrorrhagia; Epistaxis; Hemoptysis; Traumatic hemorrhage; Injury and bone fracture; The puckery pain of pyretic stranguria; Leucorrhea; Rubella pruritus; Skin ulcer swells; Scald; Hemorrhoid complicated by anal fistula; Snake bite and insect sting; Cough.[former phytomorph] ferrum Dicranopteris dichotoma, large-scale Lu Sheng pteridophyta, plant height 60-150cm.Overgrow.Rhizome horizontal walk, dark-brown, children time base portion by brown hair, after polish; Rachis five to eight times two fork branch, a long 13-16cm of rachis, the pinna rachis of more than two times is shorter, and the long 3.5-6cm of rachis is returned at end; Each time axillalry bud is avette, close by rust hair; Tool bract, avette, edge tool triangle sliver; Except first time bifurcated, all there is 1 pair of stipule shape accessory pinna all the other each time crotch both sides, obliquely, and the long 12-18cm of bottom, wide 3.2-4cm, diminishing of top, lanceolar or wide lanceolar; It is similar to stipule shape accessory pinna that accessory pinna is returned at end, long 5.5-15cm, wide 2.5-4cm, and comb dentation plumage splits and severally reaches pinna rachis; Sliver 15-40 couple, lanceolar or wire lanceolar, long 10-18mm, wide 2-3mm, several to minimum on the upside of base portion, triangle, long 4-6mm; Protruding below middle arteries and veins, lateral vein is tiltedly opened up, and often group has scun 3, and sporangiorus is circular, tiny, and 1 row, the tortuous bow place being born in scun on the upside of base portion, be made up of 5-7 Sporangium.Record in Chinese medicine voluminous dictionary.
Herba Chelonopsis chekiangensis: this product is root or the herb of Labiatae Chelonopsis plant Herba Chelonopsis chekiangensis ChelonopsischekiangensisC.Y.Wu.Root, autumn gathers, and cleans, using fresh herb; Stem and leaf, summer gathers, and dries.[nature and flavor] acrid in the mouth; Warm in nature.[function cures mainly] dispersing wind and cold; The meridian dredging; Removing food stagnancy.Main anemofrigid cold; Cough; Muscles and bones is ached; Dyspeptic abdominal distention.[former phytomorph] Herba Chelonopsis chekiangensis, herbaceos perennial, height is 60cm about.Tool rhizome; Stem is upright, four prismatics, how many tool bristle.Leaf is to life; The long 0.4-3cm of petiole; Blade lanceolar, long 3-15cm, wide 1.5-4.5cm, tip is gradually sharp, base portion wedge shape is narrow one-tenth long handle gradually, above face arteries and veins has tool to save thin calm hair, remainder dredges stiff hair, below arteries and veins dredges the thin calm hair of raw tool joint, arcuation anastomose shows, and Stockwork veinlet is sparse, the sharp shallow sawtooth of edge tool.Cyme two discrimination, axil is raw, tool 3-5 flower; Squamella 2, lanceolar, longer than bennet; Calyx mitriform, long 8-10mm, spends rear cryptomere to increase, reaches 2cm, the lance tooth that tool 4-5 is etc. not large and blunt, and outside is dredged raw tool and saved calm hair, and rear change is without hair; Corolla two brings disgrace to shape, light violet color, long 3-4cm, the full edge of upper lip, and lower lip 3 splits, in split toward larger; Stamen 4, front to longer, the micro-pubescence of filigree tool, flower pesticide 2 Room is obviously diverged, front tool whisker; Ovary 4 is split, and stigma 2 is shallow to be split.Pyrene Long Circle, tool is about the wing of 1cm.August at florescence, the fruit phase 9-10 month.Record in Chinese medicine voluminous dictionary.
1 crude drug chemical constitution:
Maclura aurantiaca ketone (Macluraxanthone).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment hepatic ascites and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment hepatic ascites are:
Maclura aurantiaca ketone 220-240 weight portion wolf beanstalk grass 4760-4770 weight portion Herba Chelonopsis chekiangensis 3200-3220 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of hepatic ascites, be made up of the crude drug of following weight portion:
Maclura aurantiaca ketone 230 weight portion wolf beanstalk grass 4765 weight portion Herba Chelonopsis chekiangensis 3210 weight portions.
Treat a pharmaceutical composition for hepatic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for hepatic ascites, it is characterized in that the treatment hepatic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of hepatic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Maclura aurantiaca ketone 220-240 weight portion wolf beanstalk grass 4760-4770 weight portion Herba Chelonopsis chekiangensis 3200-3220 weight portion;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of hepatic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Maclura aurantiaca ketone 230 weight portion wolf beanstalk grass 4765 weight portion Herba Chelonopsis chekiangensis 3210 weight portions;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of hepatic ascites, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of hepatic ascites, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat hepatic ascites medicine.
Medicine composite for curing hepatic ascites is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of hepatic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of hepatic ascites are: Maclura aurantiaca ketone 230g wolf beanstalk grass 4765g Herba Chelonopsis chekiangensis 3210g;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of hepatic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of hepatic ascites are: Maclura aurantiaca ketone 220g wolf beanstalk grass 4770g Herba Chelonopsis chekiangensis 3200g;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of hepatic ascites and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of hepatic ascites are: Maclura aurantiaca ketone 240g wolf beanstalk grass 4760g Herba Chelonopsis chekiangensis 3220g;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 161g, adds starch 189g, mixing, granulates, dry, adds microcrystalline Cellulose 52g, magnesium stearate 4.1g, and mixing, is pressed into 1000, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 162g, adds starch 143g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 100.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 246g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 14.5g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 6 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 2.3cm apart from liquid level, drips speed with per minute 45 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Experimental example 1: the experimental study for the treatment of hepatic ascites
1 clinical data
The routine patient of clinical observation treatment 30, all with clinical symptoms, sign, B ultrasonic, liver power checking for according to being diagnosed as hepatic ascites.Wherein hepatic ascites 30 ~ 40 years old 1 example, 40 ~ 50 years old 3 example, more than 50 years old 26 example.
Clinical manifestation is that enlarged abdomen heavily fortified point is full, and body icteric sclera contaminates, and face is golden yellow or as sootiness, or breast abdomen red filament continuously, poor appetite, or vomiting and nausea, constipation or loose stool, oliguria and yellow, red tongue with yellowish and greasy fur or light red tongue white and thin fur, wiry and frequent pulse or slow.
2 Therapeutic Method
Pharmaceutical composition (embodiment 1 pharmaceutical composition lot number 20110918), oral, each 1.5g, 3 times on the 1st.
3 criterions of therapeutical effect and result
3.1 criterion of therapeutical effect
Cure: transference cure, B ultrasonic and laboratory indexes normal; Effective: transference cure, B ultrasonic and laboratory indexes part normal; Effective: symptom alleviates, B ultrasonic and laboratory indexes are without change; Invalid: symptom is without improvement, and B ultrasonic and laboratory indexes are without change.
3.2 therapeutic outcome
The results are shown in Table 1.
Table 1 medicine composite for curing hepatic ascites curative effect
| Cure | Effective | Take a turn for the better | Invalid | Total effective rate % | |
| Pharmaceutical composition | 11 | 13 | 5 | 1 | 96.7 |
Take medicine 1 ~ 3 course for the treatment of, hepatic ascites observes 30 examples altogether, wherein cures 11 examples, effective 13 examples, take a turn for the better 5 examples, and invalid 1 example, total effective rate is 96.7%.
Claims (8)
1. treat a pharmaceutical composition for hepatic ascites, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Maclura aurantiaca ketone 220-240 weight portion wolf beanstalk grass 4760-4770 weight portion Herba Chelonopsis chekiangensis 3200-3220 weight portion.
2. a kind of pharmaceutical composition for the treatment of hepatic ascites according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Maclura aurantiaca ketone 230 weight portion wolf beanstalk grass 4765 weight portion Herba Chelonopsis chekiangensis 3210 weight portions.
3. a kind of pharmaceutical composition for the treatment of hepatic ascites according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of hepatic ascites according to claim 1, is characterized in that the treatment hepatic ascites medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of hepatic ascites, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Maclura aurantiaca ketone 220-240 weight portion wolf beanstalk grass 4760-4770 weight portion Herba Chelonopsis chekiangensis 3200-3220 weight portion;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of hepatic ascites according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: Maclura aurantiaca ketone 230 weight portion wolf beanstalk grass 4765 weight portion Herba Chelonopsis chekiangensis 3210 weight portions;
Preparation method:
(1) Maclura aurantiaca ketone is got by crude drug proportioning, wolf beanstalk grass, Herba Chelonopsis chekiangensis, mixing, with weight percent concentration 22% ethanol as solvent, extract at 34.5 DEG C of warm macerating, extraction time is 2 times, each extraction time is 11 hours, each solvent load is 50 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.10, filter, medicinal liquid is by D330 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting D330 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 52.5% ethanol as solvent, heating and refluxing extraction 12 times, each extraction time is 0.2 hour, each solvent load is 37 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.07, filter, medicinal liquid is by DM2 macroporous adsorptive resins, first wash with water, use weight percent concentration 89% alcoholic solution eluting DM2 macroporous adsorptive resins again, collect weight percent concentration 89% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of hepatic ascites according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of hepatic ascites according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats hepatic ascites medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047141.8A CN105535095A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating liver ascites |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610047141.8A CN105535095A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating liver ascites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105535095A true CN105535095A (en) | 2016-05-04 |
Family
ID=55815020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610047141.8A Withdrawn CN105535095A (en) | 2016-01-25 | 2016-01-25 | Medicine composition for treating liver ascites |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105535095A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581529A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Medicine composition for treating pyelonephritis and preparation method of medicine composition |
| CN106727958A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
| CN106822588A (en) * | 2016-12-10 | 2017-06-13 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
-
2016
- 2016-01-25 CN CN201610047141.8A patent/CN105535095A/en not_active Withdrawn
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581529A (en) * | 2016-12-10 | 2017-04-26 | 济南昊雨青田医药技术有限公司 | Medicine composition for treating pyelonephritis and preparation method of medicine composition |
| CN106727958A (en) * | 2016-12-10 | 2017-05-31 | 济南昊雨青田医药技术有限公司 | It is a kind of to treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
| CN106822588A (en) * | 2016-12-10 | 2017-06-13 | 济南昊雨青田医药技术有限公司 | Treat pharmaceutical composition of alcoholic hepatitis and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105535095A (en) | Medicine composition for treating liver ascites | |
| CN105287935A (en) | Traditional Chinese medicine for treating seminal vesiculitis | |
| CN105287921A (en) | Medicinal composition for treating gastric cancer and preparation method thereof | |
| CN105535043A (en) | Medicine composition for treating ascites due to cirrhosis | |
| CN104622987B (en) | A kind of pharmaceutical composition for treating chronic hepatitis liver cirrhosis and application | |
| CN104083469B (en) | A kind of Chinese medicine being used for the treatment of Senile Functional Constipation | |
| CN106540003A (en) | A kind of pharmaceutical composition for treating hyperosteogeny | |
| CN105560694A (en) | Medicine composition for treating diabetic nephropathy and preparation method thereof | |
| CN105327009A (en) | Medicinal composition for treating malignant tumor and preparation method thereof | |
| CN105497119A (en) | Medicine composition for treating benign prostatic hyperplasia | |
| CN106109551A (en) | A kind of pharmaceutical composition preventing and treating chloasma | |
| CN105521226A (en) | Traditional Chinese medicinal composition for treating iron-deficiency anemia and preparation method of traditional Chinese medicinal composition | |
| CN105535265A (en) | Pharmaceutical composition for treating pancreatic cancer | |
| CN106581095A (en) | Medicinal composition for treating neurodermatitis | |
| CN106668347A (en) | Medical composition for treating thyroid diseases | |
| CN106038899A (en) | Pharmaceutical composition capable of preventing and treating esophagus cancer and preparation method of pharmaceutical composition | |
| CN106539846A (en) | Pharmaceutical composition of anti-treating cervicitis and preparation method thereof | |
| CN106727851A (en) | Prevent and treat pharmaceutical composition of ovarian cyst and preparation method thereof | |
| CN105560361A (en) | Medicine composition for treating esophagus cancer at middle and late stages | |
| CN105641036A (en) | Medicine composition for treating depression and preparation method thereof | |
| CN105267286A (en) | Pharmaceutical composition for treating infantile qi-deficiency constipation | |
| CN106581263A (en) | Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof | |
| CN106539838A (en) | Prevent and treat the pharmaceutical composition of neurodermatitis | |
| CN106581434A (en) | Pharmaceutical composition for prevention and treatment of periodontitis and preparation method thereof | |
| CN107029006A (en) | A kind of pharmaceutical composition for being used to treat fibroid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160504 |